Neurological aspects of hallucinogenic drugs.
D004290:DOM 2,5-Dimethoxy-4-Methylamphetamine / Q000494:pharmacology; D000662:Amphetamines / Q000008:administration & dosage / Q000494:pharmacology / Q000633:toxicity; D000818:Animals; D001921:Brain / Q000187:drug effects*; D001925:Brain Damage, Chronic / Q000139:chemically induced; D002188:Cannabis / Q000009:adverse effects / Q000494:pharmacology; D002395:Catecholamines / Q000502:physiology; D004305:Dose-Response Relationship, Drug; D013759:Dronabinol / Q000494:pharmacology; D006213:Hallucinogens / Q000494:pharmacology*; D000882:Haplorhini; D006801:Humans; D007275:Injections, Intravenous; D008238:Lysergic Acid Diethylamide / Q000494:pharmacology; D008635:Mescaline / Q000494:pharmacology; D004130:N,N-Dimethyltryptamine / Q000494:pharmacology; D009290:Narcolepsy / Q000188:drug therapy; D011562:Psilocybin / Q000494:pharmacology; D051381:Rats; D012640:Seizures / Q000139:chemically induced; D012702:Serotonin Antagonists; D019966:Substance-Related Disorders
D000662:Amphetamines; D002395:Catecholamines; D006213:Hallucinogens; D012702:Serotonin Antagonists; D004290:DOM 2,5-Dimethoxy-4-Methylamphetamine; D011562:Psilocybin; D013759:Dronabinol; D008238:Lysergic Acid Diethylamide; D008635:Mescaline; D004130:N,N-Dimethyltryptamine